Hannah Slater
Articles
FDA Approves Atezolizumab Combo for Advanced Melanoma
July 31, 2020
Article
The FDA approved atezolizumab plus cobimetinib and vemurafenib for the treatment of patients with BRAF V600 mutation-positive advanced melanoma.
Nationwide Decrease Seen in Cancer-Related Encounters Due to the COVID-19 Pandemic
July 30, 2020
Article
These findings have serious implications for future cancer care and underscore the need to resume cancer care and screening.
FDA Accepts 2 New Supplemental Biologics License Applications for Pembrolizumab in TNBC
July 30, 2020
Article
Marking the first US applications for pembrolizumab in breast cancer, the applications are based on data from the KEYNOTE-355 and KEYNOTE-522 trials, respectively.
In Light of COVID-19 Pandemic, Reassessment of Childhood Cancer Care Delivery May Be Needed
July 28, 2020
Article
This research suggested the need for reassessment of the methods by which childhood cancer treatment delivery are approached during crises.
Educational Tool Assists Patients, Caregivers of Cancer in Learning About Hospice
July 27, 2020
Article
Though the video did not have a statistically significant impact, those assigned to watch the video appeared to be more informed about hospice care and reported more favorable perceptions of hospice.
Relugolix May Become New Standard of Care for Advanced Prostate Cancer
June 01, 2020
Article
Relugolix (Relumina) demonstrated superiority over leuprolide (Lupron) in sustained testosterone (T)-suppression through 48 weeks, fast T-recovery after discontinuation, and a 50% reduction in major adverse cardiovascular events (MACE) in patients with advanced prostate cancer.
FDA Grants Priority Review to CC-486 for the Treatment of Acute Myeloid Leukemia
May 01, 2020
Article
The FDA granted priority review to a new drug application for CC-486 for the maintenance treatment of adult patients with acute myeloid leukemia based on efficacy and safety results from the pivotal phase III QUAZAR AML-001 study.
FDA Grants Priority Review to Sodium Thiosulfate for Ototoxicity Prevention
April 14, 2020
Article
The FDA granted priority review to the new drug application for sodium thiosulfate for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to
FDA Grants Priority Review to Pembrolizumab Monotherapy for TMB-High Tumors
April 07, 2020
Article
The FDA granted priority review to pembrolizumab monotherapy for the treatment of adult and pediatric patients with unresectable or metastatic TMB-high solid tumors who have progressed following prior treatment and who have no satisfactory alternative treatment options.
FDA Grants Priority Review to Tafasitamab/Lenalidomide Combination for DLBCL
March 02, 2020
Article
The FDA granted priority review to a biologics license application for tafasitamab in combination with lenalidomide for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.